DSpace About DSpace Software 日本語

01 奈良県立医科大学 >
012 大学院 >
0122 学位請求論文 >
01221 博士論文(医学) >
2022年度 >

Please use this identifier to cite or link to this item: http://hdl.handle.net/10564/4098

Title: Overexpression of microRNA-345 Affects the Invasive Capacity of Pancreatic Ductal Adenocarcinoma Cell Lines by Suppressing MUC1 and TJP2 Expression
Other Titles: microRNA-345の過剰発現は、MUC1およびTJP2の発現を抑制することにより、膵管腺癌細胞株の浸潤能に影響を及ぼす
Authors: Tatsumi, Shigenobu
Fujii, Tomomi
Sugimoto, Aya
Sekita-Hatakeyama, Yoko
Morita, Kohei
Uchiyama, Tomoko
Itami, Hiroe
Takeda, Maiko
Yamazaki, Masaharu
Sho, Masayuki
Ohbayashi, Chiho
Keywords: PDAC
cell proliferation
Issue Date: 25-May-2022
Publisher: MDPI
Citation: Applied Sciences Vol.12 No.11 Article No.5351 (2022 May)
Abstract: The majority of pancreatic carcinomas are pancreatic ductal adenocarcinomas (PDAC), and the presence of non-invasive pancreatic intraepithelial neoplasia or intraductal papillary mucinous neoplasm, as an associated lesion, is considered important. These microscopic hyperplastic or grossly papillomatous lesions exhibit varying degrees of morphological atypia and may develop into invasive carcinomas. In this study, we investigated whether mucin-1 (MUC1) is involved in the progression of pancreatic carcinoma and examined the mechanisms by which microRNAs regulate MUC1 expression in vitro. In PDAC cell lines, suppression of MUC1 expression reduced cell proliferation and invasion; PDAC cell lines transfected with an miR-345 precursor suppressed the expression of MUC1, and reduced cell proliferation and invasion. Tight junction protein 2 (TJP2), a putative target of miR-345, is regulated by MUC1. The suppression of TJP2 expression reduced cell proliferation by inducing apoptosis. These results suggest that MUC1 and TJP2, the putative target molecules of miR-345, are critical in maintaining the invasive potential of pancreatic carcinoma cells, and regulating their expression may prevent the progression of non-invasive pancreatic intraductal lesions to invasive carcinomas. This study provides new insights for the development of novel molecular targeted therapies for pancreatic carcinomas.
Description: 博士(医学)・甲第866号・令和5年3月15日
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
URI: http://hdl.handle.net/10564/4098
DOI: https://doi.org/10.3390/app12115351
Academic Degrees and number: 24601甲第866号
Degree-granting date: 2023-03-15
Degree name: 博士(医学)
Degree-granting institutions: 奈良県立医科大学
Appears in Collections:2022年度

Files in This Item:

File Description SizeFormat
01甲866本文の要旨.pdf103.32 kBAdobe PDFView/Open
02甲866審査要旨.pdf197.08 kBAdobe PDFView/Open
03甲866本文.pdf4.15 MBAdobe PDFView/Open
04甲866Suppl.pdf1.25 MBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.


Valid XHTML 1.0! DSpace Software Copyright © 2002-2010  Duraspace - Feedback